Molecular profile
- Sequence
- Lys-Glu-Asp-Ala
- Molecular Formula
- C 18 H 31 N 5 O 9
- Molecular Weight
- 461.5\ \mathrm{g mol^{-1}}
- PubChem CID
- 87919683
- CAS Number
- 195875-84-4
Peptide research profile
Livagen
Livagen is a short peptide that impacts DNA structure and gene expression. It has shown potential in rejuvenating cells, enhancing immune responses, and offering benefits for the heart, gastrointestinal tract, and nervous system. It also has anti-aging properties by activating genes typically silenced with age.
Dosing literacy
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context—not a protocol or recommendation.
Recorded amount context
Mass amounts available for comparison
- Lower range1 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range5 mgDose
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Schedule literacy
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Research best practices
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Research orientation
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 01
DNA Organization in Eukaryotes
Understanding DNA packaging and organization in eukaryotic cells
- 02
Chromatin's Role in Gene Expression Control
How Livagen affects chromatin structure and gene expression
- 03
Lymphocytes and Immune System
Livagen's effects on immune system cells and cardiac health
- 04
Livagen and Pain Management
Livagen's role in pain control and enkephalin regulation
- 05
Livagen and the Gastrointestinal Tract
Livagen's effects on GI tract mucosal barrier and protection
- 06
Livagen and Aging
Livagen's anti-aging effects through DNA decondensation
Evidence map
What is known—and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Source review pending
DNA Organization in Eukaryotes
Understanding DNA packaging and organization in eukaryotic cells
- Source review pending
Chromatin's Role in Gene Expression Control
How Livagen affects chromatin structure and gene expression
Recorded protocol library
Amounts recorded for Livagen
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 01
Dose · lower endpoint
1 mg
Sign in for schedule, duration and source context.
- 02
Dose · upper endpoint
5 mg
Sign in for schedule, duration and source context.
Technical reference
Identity, limitations and unknowns
Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Source review
1 links awaiting verification
- Source link · pmc.ncbi.nlm.nih.govVerification pending · Source review pending